But Eli Lilly got there first. With the FDA's approval in early July of Kisunla, its new medicine for Alzheimer's developed ...

As quantitative data replaced qualitative descriptions in the ads, and as information about severe adverse effects was ...

New AI software promises to make diagnosing dementia quicker and more accurate, helping doctors provide timely and effective ...

Compared to the placebo, patients treated with Kisunla had a 35% slower cognitive and functional decline at 18 months of ...

We recently compiled a list of the 12 Best Dividend Stocks For Steady Growth. In this article, we are going to take a look at ...

Analyst Akash Tewari of Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), boosting the price target to ...

Boston University researchers developed an AI tool that accurately diagnoses 10 types of dementia, improving diagnosis ...

Alzheimer’s drug, donanemab (marketed as Kisunla), could be rejected for use by the National Health Service (NHS) in Britain, ...

Shortly after a U.K. watchdog declined to endorse Biogen's ( NASDAQ: BIIB) Alzheimer's drug Leqembi for use in the country's ...

NeuroXT's state-of-the-art technology uses MRI data to understand the interaction between beta-amyloid and tau proteins—key players in Alzhemer's disease. This innovative approach has the potential to ...

Doctors said the drug Kisunla is the first drug to be approved by the FDA for Alzheimer’s in more than a decade giving hope ...

Even within a group of people who are all 80, depending on where you live, you might be twice as likely to actually get a ...